STOCK TITAN

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management

Clearside Biomedical (Nasdaq: CLSD) has appointed Tony Gibney as the new Chair of its Board of Directors, effective November 1, 2024. Gibney, who joined as an independent director in April 2024, succeeds Clay Thorp, who remains on the Board. Gibney brings over 30 years of biotechnology industry experience, most recently serving as Executive VP, Chief Business & Strategy Officer at Iveric Bio until its acquisition by Astellas Pharma in July 2023. The company highlights his strategic leadership in ophthalmics and capital markets expertise, particularly noting the recent ODYSSEY Phase 2b results with CLS-AX in wet AMD, which showed promising potential.

Clearside Biomedical (Nasdaq: CLSD) ha nominato Tony Gibney come nuovo presidente del Consiglio di Amministrazione, con effetto dal 1 novembre 2024. Gibney, che è entrato come direttore indipendente nell'aprile 2024, succede a Clay Thorp, che rimane nel Consiglio. Gibney porta con sé oltre 30 anni di esperienza nell'industria biotecnologica, avendo recentemente ricoperto il ruolo di Vice Presidente Esecutivo e Chief Business & Strategy Officer presso Iveric Bio fino all'acquisizione da parte di Astellas Pharma nel luglio 2023. L'azienda evidenzia la sua leadership strategica nel settore oftalmico e la sua esperienza nei mercati dei capitali, notando in particolare i recenti risultati della Fase 2b ODYSSEY con CLS-AX nella degenerazione maculare umida (AMD), che hanno mostrato un potenziale promettente.

Clearside Biomedical (Nasdaq: CLSD) ha nombrado a Tony Gibney como el nuevo presidente de su Junta Directiva, con efecto a partir del 1 de noviembre de 2024. Gibney, quien se unió como director independiente en abril de 2024, sucede a Clay Thorp, quien permanece en la Junta. Gibney aporta más de 30 años de experiencia en la industria biotecnológica, habiendo desempeñado recientemente el cargo de Vicepresidente Ejecutivo y Director de Negocios y Estrategia en Iveric Bio hasta su adquisición por Astellas Pharma en julio de 2023. La compañía destaca su liderazgo estratégico en oftalmología y su experiencia en mercados de capital, señalando especialmente los recientes resultados de la Fase 2b ODYSSEY con CLS-AX en la degeneración macular húmeda (AMD), que mostraron un potencial prometedor.

Clearside Biomedical (Nasdaq: CLSD)는 2024년 11월 1일부터 Tony Gibney를 이사회 의장으로 임명했습니다. Gibney는 2024년 4월 독립 이사로 합류하였으며, Clay Thorp의 뒤를 이어 이사회에 남게 됩니다. Gibney는 생명공학 산업에서 30년 이상의 경력을 가지고 있으며, 최근에는 2023년 7월 Astellas Pharma에 인수될 때까지 Iveric Bio에서 집행 부사장 및 사업 및 전략 책임자로 재직했습니다. 회사는 그의 안구 분야에서의 전략적 리더십과 자본 시장 전문성을 강조하며, 최근 CLS-AX에 대한 ODYSSEY 2b 임상 시험 결과가 습성 AMD에서 유망한 가능성을 보여주었다고 특히 언급합니다.

Clearside Biomedical (Nasdaq: CLSD) a nommé Tony Gibney comme nouveau président de son conseil d'administration, avec effet au 1er novembre 2024. Gibney, qui a rejoint en tant que directeur indépendant en avril 2024, succède à Clay Thorp, qui reste au conseil. Gibney apporte plus de 30 ans d'expérience dans l'industrie biotechnologique, ayant récemment occupé le poste de vice-président exécutif et directeur des affaires et de la stratégie chez Iveric Bio jusqu'à son acquisition par Astellas Pharma en juillet 2023. L'entreprise souligne son leadership stratégique dans le domaine de l'ophtalmologie et son expertise sur les marchés financiers, notant en particulier les récents résultats de la phase 2b ODYSSEY avec CLS-AX dans la DMLA humide, qui ont montré un potentiel prometteur.

Clearside Biomedical (Nasdaq: CLSD) hat Tony Gibney zum neuen Vorsitzenden des Vorstands ernannt, der am 1. November 2024 in Kraft tritt. Gibney, der im April 2024 als unabhängiger Direktor beigetreten ist, tritt die Nachfolge von Clay Thorp an, der weiterhin im Vorstand bleibt. Gibney bringt über 30 Jahre Erfahrung in der Biotechnologiebranche mit, zuletzt war er als Executive VP und Chief Business & Strategy Officer bei Iveric Bio tätig, bis das Unternehmen im Juli 2023 von Astellas Pharma übernommen wurde. Das Unternehmen hebt seine strategische Führung im Bereich Augenheilkunde und seine Expertise im Kapitalmarkt hervor, insbesondere die kürzlichen ODYSSEY Phase 2b Ergebnisse mit CLS-AX bei feuchter AMD, die vielversprechendes Potenzial zeigten.

Positive
  • Recent ODYSSEY Phase 2b trial results for CLS-AX in wet AMD showed promising potential
  • New Board Chair brings extensive industry experience and capital markets expertise
  • Company has a commercial product and multiple development programs in progress
Negative
  • None.

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside’s Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board.

George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, “Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experience in the ophthalmic industry and insightful capital markets expertise. We are delighted to have Tony take on the role as Chair of the Board. We are also deeply grateful to Clay for his significant contributions to Clearside as Board Chair and we look forward to his continued guidance.”

“Clearside has a valuable and differentiated pipeline and drug delivery platform with a commercial product and multiple promising development programs ongoing both internally and by our partners. In particular, the recent ODYSSEY Phase 2b results with CLS-AX in wet AMD reveal a potential best in class profile that will be strategically important in a very prevalent retinal disease. I am honored to be named Chair at this important time for the Company as we continue expanding the use of our market-leading suprachoroidal delivery platform on our own and with corporate partners to treat a variety of retinal diseases,” concluded Mr. Gibney.

Tony Gibney is an experienced biotechnology executive and former investment banker who brings over 30 years of experience dedicated to advising and leading biotechnology companies in the U.S. and Europe on business strategy, collaboration transactions, financings, and mergers and acquisitions. Most recently, Mr. Gibney served as the Executive Vice President, Chief Business & Strategy officer of Iveric Bio, Inc. until the company’s acquisition by Astellas Pharma Inc. in July 2023. Prior to that, Mr. Gibney served as Chief Financial Officer and Chief Business Officer at Fog Pharmaceuticals, Inc., where he oversaw its business development, strategy and finance functions, and he served as Executive Vice President and Chief Business Officer at Achillion Pharmaceuticals, where he led the sale of Achillion to Alexion Pharmaceuticals, Inc. in 2020. Before Achillion, Mr. Gibney was a Managing Director and Co-head of the biotechnology investment banking team at Leerink Partners LLC, and Managing Director of Merrill Lynch’s healthcare group. He currently serves on the boards of directors of LAPIX Therapeutics, Inc. and InflaRx N.V. and provides strategic consulting services to select biotechnology companies. Mr. Gibney received a B.A. in Economics and a B.A. in History from Yale University.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), recently completed a Phase 2b clinical trial, and planning for a Phase 3 program is underway. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the Company’s intention to continue to expand the use of its suprachoroidal delivery platform to treat a variety of retinal diseases, the potential of the Company’s development programs as well as the potential benefits to the Company of Mr. Gibney’s leadership experience and capital markets expertise. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC) on March 12, 2024, Clearside’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 12, 2024 and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.


FAQ

When did Tony Gibney become Chair of Clearside Biomedical (CLSD)?

Tony Gibney became Chair of Clearside Biomedical's Board of Directors effective November 1, 2024.

What are the recent clinical trial results mentioned for Clearside Biomedical (CLSD)?

The PR mentions promising ODYSSEY Phase 2b trial results with CLS-AX in wet AMD, indicating a potential best-in-class profile.

What was Tony Gibney's most recent position before joining Clearside Biomedical (CLSD)?

Tony Gibney served as Executive Vice President, Chief Business & Strategy Officer of Iveric Bio until its acquisition by Astellas Pharma in July 2023.

Clearside Biomedical, Inc.

NASDAQ:CLSD

CLSD Rankings

CLSD Latest News

CLSD Stock Data

80.39M
70.22M
7.39%
23.17%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA